SHERIDAN, WYOMING – May 9, 2025 – Galderma Group AG (SIX: GALD), a leader in dermatology innovation, has successfully held its first Annual General Meeting (AGM), where all proposals from the Board of Directors received overwhelming approval. The meeting, which took place via live webcast, marked a significant milestone for the company, highlighting its ongoing commitment to transparency and shareholder engagement.
A Strong Year for Galderma
In a show of solid backing from its shareholders, Galderma has announced a gross dividend of 0.15 CHF per dividend-bearing share. This payout will be distributed from reserves stemming from capital contributions, further reflecting the company's strong financial position. The approval of this dividend demonstrates the company's continued focus on delivering value to its investors.
Leadership and Board Reappointments
The AGM also saw the reelection of all current members of the Board of Directors, including key leaders like Thomas Ebeling (Chair), Dr. Flemming Ørnskov, Michael Bauer, and others. This decision ensures that Galderma's leadership will continue to drive forward its mission of advancing dermatology through innovation. Additionally, Roberto Marques was elected to join the Board, further strengthening the company's leadership.
Key Approvals for Galderma's 2024 Reports
Shareholders also approved the company’s 2024 Annual Financial Statements, Non-Financial Report, and Compensation Report. These reports reflect Galderma's commitment to maintaining high standards of governance and transparency, ensuring that all stakeholders are informed of the company’s financial health and future direction.
Looking Ahead: What’s Next for Galderma?
As Galderma continues to lead the dermatology market, shareholders can look forward to more innovations and developments within the dermatology space. Galderma’s presence in over 90 countries, combined with its science-backed products in Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology, positions it well for further growth and success.
Conclusion
With a solid foundation and strong leadership, Galderma is poised for continued success in the fast-growing dermatology market. Shareholders can take pride in the company's achievements and look forward to the positive impact its advancements will have on consumers and healthcare professionals alike.
To learn more about Galderma’s future plans and developments, visit www.galderma.com.